Effect of Ezetimibe on Oxidized Low-density Lipoprotein (LDL) Cholesterol
Launched by HOTEL DIEU DE FRANCE HOSPITAL · Nov 4, 2009
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • CAD or CAD equivalent
- Exclusion Criteria:
- • Prior CABG or PCI within 3 months Prior use of ezetimibe within 3 months Receiving atorvastatin 40 mg/day or 80 mg/day or any dose of rosuvastatin CHF NYHA stage \>2 Creatinin clearance \< 30 ml/min
About Hotel Dieu De France Hospital
Hotel Dieu de France Hospital is a renowned healthcare institution committed to advancing medical science through innovative clinical research. With a strong emphasis on patient-centered care, the hospital combines state-of-the-art facilities with a multidisciplinary team of experienced healthcare professionals. The institution actively sponsors clinical trials aimed at evaluating new therapies and treatment protocols, ensuring rigorous adherence to ethical standards and regulatory guidelines. By fostering collaboration with academic and research partners, Hotel Dieu de France Hospital seeks to contribute significantly to the development of effective healthcare solutions that enhance patient outcomes and improve quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Achrafieh, Beirut, Lebanon
Patients applied
Trial Officials
rabih azar, md
Principal Investigator
Hotel Dieu
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials